Literature DB >> 10411940

Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells.

R Marches1, R Hsueh, J W Uhr.   

Abstract

The p21(WAF1) (p21) cyclin-dependent kinase inhibitor plays a major role in regulating cell cycle arrest. It was recently reported that the p53-independent elevation of p21 protein levels is essential in mediating the G(1) arrest resulting from signal transduction events initiated by the crosslinking of membrane IgM on Daudi Burkitt lymphoma cells. Although the role of p21 in cell cycle regulation is well documented, there is little information concerning its role in antibody-mediated apoptosis. In the present study, we examined the involvement of p21 in the regulation of apoptosis by suppressing its induction in anti-IgM-treated Daudi cells through a p21 antisense expression construct approach. Reduction in induced p21 protein levels resulted in diminished G(1) arrest and increased apoptosis. The increased susceptibility to anti-IgM-mediated apoptosis was associated with increased caspase-3-like activity and poly-(ADP)ribose polymerase cleavage. These data suggest that p21 may directly interfere with the caspase cascade, thus playing a dual role in regulating both cell cycle progression and apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411940      PMCID: PMC17581          DOI: 10.1073/pnas.96.15.8711

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas.

Authors:  J Hasbold; G G Klaus
Journal:  Eur J Immunol       Date:  1990-08       Impact factor: 5.532

2.  Anti-IgM-mediated growth inhibition of a human B lymphoma cell line is independent of phosphatidylinositol turnover and protein kinase C activation and involves tyrosine phosphorylation.

Authors:  M Beckwith; W J Urba; D K Ferris; C E Freter; D B Kuhns; C M Moratz; D L Longo
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

3.  Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.

Authors:  A Demidem; T Lam; S Alas; K Hariharan; N Hanna; B Bonavida
Journal:  Cancer Biother Radiopharm       Date:  1997-06       Impact factor: 3.099

Review 4.  Therapy of lymphoma directed at idiotypes.

Authors:  R Levy; R A Miller
Journal:  J Natl Cancer Inst Monogr       Date:  1990

5.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Authors:  R M Hudziak; G D Lewis; M Winget; B M Fendly; H M Shepard; A Ullrich
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

6.  Antigen receptor-induced cell cycle arrest in WEHI-231 B lymphoma cells depends on the duration of signaling before the G1 phase restriction point.

Authors:  D M Page; A L DeFranco
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

7.  Humanization of an anti-p185HER2 antibody for human cancer therapy.

Authors:  P Carter; L Presta; C M Gorman; J B Ridgway; D Henner; W L Wong; A M Rowland; C Kotts; M E Carver; H M Shepard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

8.  Cancer dormancy: studies of the murine BCL1 lymphoma.

Authors:  J W Uhr; T Tucker; R D May; H Siu; E S Vitetta
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

9.  Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition.

Authors:  L J Picker; J R Treer; B Ferguson-Darnell; P A Collins; D Buck; L W Terstappen
Journal:  J Immunol       Date:  1993-02-01       Impact factor: 5.422

10.  Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody.

Authors:  H Taji; Y Kagami; Y Okada; M Andou; Y Nishi; H Saito; M Seto; Y Morishima
Journal:  Jpn J Cancer Res       Date:  1998-07
View more
  11 in total

1.  Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner.

Authors:  Elizabeth O Lobo; Zhifang Zhang; John E Shively
Journal:  J Leukoc Biol       Date:  2009-05-19       Impact factor: 4.962

Review 2.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

Review 3.  Controversies in clinical cancer dormancy.

Authors:  Jonathan W Uhr; Klaus Pantel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

4.  The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities.

Authors:  Julio A Aguirre-Ghiso
Journal:  Cell Cycle       Date:  2006-08-15       Impact factor: 4.534

5.  HDAC inhibitors stimulate LIFR when it is repressed by hypoxia or PTHrP in breast cancer.

Authors:  Courtney M Edwards; Miranda E Clements; Lawrence A Vecchi; Jasmine A Johnson; Rachelle W Johnson
Journal:  J Bone Oncol       Date:  2021-12-01       Impact factor: 4.072

6.  Position-dependent expression of GADD45alpha in rat brain tumours.

Authors:  Antonio Brú; Carlos del Fresno; Alessandra Soares-Schanoski; Sonia Albertos; Isabel Brú; Amelia Porres; Eduardo Rollán-Landeras; Ana Dopazo; David Casero; Vanesa Gómez-Piña; Lourdes García; Francisco Arnalich; Rebeca Alvarez; Alexandro Rodríguez-Rojas; Pablo Fuentes-Prior; Eduardo López-Collazo
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

7.  Activation of cell cycle regulatory proteins in the apoptosis of terminally differentiated oligodendrocytes.

Authors:  M Strazza; A Luddi; A Brogi; M Carbone; M Riccio; S Santi; M Melli; E Costantino-Ceccarini
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

8.  Deficiency of the cyclin kinase inhibitor p21(WAF-1/CIP-1) promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity.

Authors:  Brian R Lawson; Roberto Baccala; Jianxun Song; Michael Croft; Dwight H Kono; Argyrios N Theofilopoulos
Journal:  J Exp Med       Date:  2004-02-16       Impact factor: 14.307

Review 9.  The current paradigm and challenges ahead for the dormancy of disseminated tumor cells.

Authors:  Emma Risson; Ana Rita Nobre; Veronique Maguer-Satta; Julio A Aguirre-Ghiso
Journal:  Nat Cancer       Date:  2020-07-06

10.  Tumour dormancy in breast cancer: an update.

Authors:  Muriel Brackstone; Jason L Townson; Ann F Chambers
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.